- Generic name
- Levetiracetam
- Strength
- 500 mg/5 ml
- Dosage form
- Injection
- Manufactured by
- Advanced Chemical Industries PLC
Citazar Iv Injection
About Citazar Iv 500 mg/5 ml Injection
Citazar Iv is a levetiracetam injection used as an add-on treatment for certain types of epilepsy. It works by helping to calm abnormal electrical activity in the brain that can lead to seizures.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Citazar Iv 500 mg/5 ml Injection?
Citazar Iv is a 500 mg/5 ml injection containing levetiracetam, an anti-epileptic medicine. It is used as adjunctive therapy for partial-onset seizures, with or without secondary generalisation, in adults, adolescents, children and infants from one month of age. It belongs to a group of medicines called adjunct anti-epileptic drugs, meaning it is added to other epilepsy treatment. The injection is given by a healthcare professional. The doctor decides the dose, frequency and course of treatment based on the patient's condition and response.
Uses of Citazar Iv
Citazar Iv is used as add-on therapy for partial-onset seizures, with or without secondary generalisation, in adults, adolescents, children and infants from one month of age. It is prescribed when other epilepsy medicines are used together to help control seizures. This injection form is for use under medical supervision. The doctor decides how it fits into the overall treatment plan.
How to use Citazar Iv
Citazar Iv is an injection, so it is given by a doctor or nurse in a healthcare setting. Do not attempt to inject it yourself. The doctor will decide the dose, how often it is given, and how long the course lasts. Tell the healthcare team about any other medicines the patient takes. If a dose is missed, ask the doctor or pharmacist what to do; do not change the schedule on your own.
Side effects of Citazar Iv
Common side effects in adults may include sleepiness, weakness, infection and dizziness. In children, fatigue, aggression, nasal congestion, decreased appetite and irritability have been reported. Rarely, decreased blood cell counts can occur, generally at the beginning of treatment. Very rarely, acute kidney injury has been associated with levetiracetam. Tell the doctor or nurse if any side effect bothers the patient or does not go away.
Safety and precautions
Citazar Iv should not be used by anyone with a known hypersensitivity to levetiracetam, other pyrrolidone derivatives, or any ingredient of the injection. Patients with kidney problems may need dose adjustment, and those with severely impaired liver function should have kidney function checked before the dose is chosen. Levetiracetam is not recommended during pregnancy or in women who could become pregnant and are not using contraception unless clinically necessary. It passes into breast milk, so breastfeeding is not recommended; if treatment is needed while breastfeeding, the benefits and risks should be weighed. Always ask the doctor first about any concerns.
Frequently asked questions
What does the dosage form and strength mean?
Citazar Iv is supplied as an injection. The strength 500 mg/5 ml means each 5 ml of the injection contains 500 mg of levetiracetam. It is given by a healthcare professional; the doctor decides the dose and course.
What is Citazar Iv used for and what kind of medicine is it?
Citazar Iv is an adjunct anti-epileptic medicine. It is used as add-on therapy for partial-onset seizures, with or without secondary generalisation, in adults, adolescents, children and infants from one month of age. It is given under medical supervision.
Who should avoid Citazar Iv or ask the doctor first?
Anyone with hypersensitivity to levetiracetam, other pyrrolidone derivatives, or any ingredient of the injection should avoid it. Patients with kidney or liver problems, pregnant women, women who could become pregnant without contraception, and breastfeeding women should ask the doctor first.
Can Citazar Iv be used with other epilepsy medicines?
Citazar Iv is used as add-on therapy, meaning it is taken together with other epilepsy medicines. The doctor will decide how it fits into the overall treatment plan. Always tell the doctor about all other medicines being used.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.